PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 31/41, 31/415, 31/44, 31/455

A1

(11) International Publication Number: WO 00/38676

(43) International Publication Date: 6 July 2000 (06.07.00)

(21) International Application Number: PCT/EP99/10330

(22) International Filing Date: 22 December 1999 (22.12.99)

(30) Priority Data:

98811257.9	23 December 1998 (23.12.98)	EP
98811258.7	23 December 1998 (23.12.98)	EP

(71) Applicant *(for all designated States except AT US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS–ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59 A–1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BULLOCK, Gillian, Rosemary [GB/GB]; East Holme Farm, Maresfield, Uckfield, E.Sussex TN22 3AY (GB). DE GASPARO, Marc [CH/CH]; Es Planches 123a, CH–2842 Rossemaison (CH). GANTER, Sabina, Maria [DE/DE]; Neustädtle 16, D–79365 Rheinhausen (DE).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH–4002 Basel (CH).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: USE OF AT–1 RECEPTOR ANTAGONIST OR AT–2 RECEPTOR MODULATOR FOR TREATING DISEASES ASSOCIATED WITH AN INCREASE OF AT–1 OR AT–2 RECEPTORS

(57) Abstract

The invention relates to the use of an AT_1 receptor antagonist or an AT_2 receptor modulator, respectively, or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT_1 receptors in the sub–epithelial area or increase of AT_2 receptors in the epithelia.